A randomized double-blind study of inosiplex (Isoprinosine) therapy in patients with alopecia totalis

摘要: Twenty-five of 34 patients with alopecia totalis at least 1 year's duration and associated defects in cell-mediated immunity completed a randomized, double-blind, placebo-controlled crossover trial the therapeutic effect inosiplex, synthetic immunomodulator. Each patient received 20 weeks treatment inosiplex placebo randomized order. Eleven were identified clinically as responders to terms hair regrowth. Scalp biopsy results correlated well drug therapy. Enhanced immune function was found majority responding patients; however, statistical analysis entire population revealed limited significant differences. No experienced adverse side effects attributable These show that is safe effective therapy for certain totalis. (J Am Acad Dermatol 1987;16:977-83.)